Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Employees

3,035

Sector

Biotechnology & Medical Research

Calendar

Aug. 26 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-18	140.70 $	+0.86%	10,315,560
25-07-17	139.50 $	+10.71%	16,822,560
25-07-16	126.00 $	+4.39%	12,011,770
25-07-15	120.70 $	+2.12%	10,442,910
25-07-14	118.20 $	+4.42%	9,761,890

Delayed Quote Hong Kong S.E., July 18, 2025 at 04:08 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

128.72CNY

Average target price

104.36CNY

Spread / Average Target

-18.93%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2025-07-18 am EDT			5-day change	1st Jan Change
140.70 ^HKD	+0.86%		+24.29%	+131.80%

Jul. 18	Nomura Adjusts Akeso's Price Target to HK$120.64 From HK$99.66, Keeps at Neutral	MT
Jul. 16	Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	CI

Capitalization	116B 126B 16.09B 13.81B 12.86B 11.97B 22.08B 1,386B 24.66B 155B 58.67B 650B 60.36B 59.11B 2,389B	P/E ratio 2025 *	1,287x	P/E ratio 2026 *	129x
Enterprise value	116B 127B 16.12B 13.83B 12.89B 11.99B 22.13B 1,389B 24.71B 156B 58.78B 651B 60.48B 59.23B 2,393B	EV / Sales 2025 *	32.9x	EV / Sales 2026 *	20.7x
Free-Float	74.46%	Yield 2025 *	-	Yield 2026 *	-

Nomura Adjusts Akeso's Price Target to HK$120.64 From HK$99.66, Keeps at Neutral	Jul. 18	MT
Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	Jul. 16	CI
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	Jul. 03	RE
Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	Jul. 03	CI
Akeso, Inc. Presents Subgroup Analysis Data from the Phase III Company-16 Trial	Jun. 15	CI
TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong	Jun. 12	MT
Akeso Gets China Nod for Cervical Cancer Drug	Jun. 05	MT
Akeso Says NMPA Approved SNDA For Cadonilimab	Jun. 04	RE
Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%	Jun. 03	MT
Akeso Grants Share Options, Restricted Share Units	May. 26	MT
Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14	Apr. 28	MT
Akeso Gets China Nod for Lung Cancer Drug Indication	Apr. 28	MT
Akeso, Inc. Announces the Global First-In-Class Pd-1/Vegf Bi-Specific Antibody,Ivonescimab, Has Received Approval from the National Medical Products Administration	Apr. 27	CI

Nomura Adjusts Akeso's Price Target to HK$120.64 From HK$99.66, Keeps at Neutral	Jul. 18	MT
Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14	Apr. 28	MT
Nomura Adjusts Akeso's Price Target to HK$75.14 From HK$66.40, Keeps at Buy	Feb. 18	MT
GF Securities Starts Akeso at Buy with HK$81.59 Price Target	Dec. 11	MT
Nomura Adjusts Akeso's Price Target to HK$66.40 From HK$46.04, Keeps at Buy	24-09-10	MT

Akeso, Inc. Stock

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Valuation: Akeso, Inc.

Chart: Akeso, Inc.

Latest news: Akeso, Inc.

Last Transcript: Akeso, Inc.

Analysts' recommendations: Akeso, Inc.

Press Releases: Akeso, Inc.

News in other languages: Akeso, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Akeso, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Akeso Announces First Patient Enrolled in the Phase III Trial(AK112-312/HARMONi-GI6)of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	Jul. 16	AQ
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	Jul. 15	PR
Akeso's First Bispecific ADC Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy	Jul. 04	AQ
Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab	Jun. 04	PR
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates	Feb. 25	AQ

1 day	+0.86%
1 week	+24.29%
Current month	+53.02%
1 month	+48.50%
3 months	+69.62%
6 months	+137.87%
Current year	+131.80%

1 week	112.6	142.8
1 month	89	142.8
Current year	54	142.8
1 year	38.8	142.8
3 years	19.22	142.8
5 years	11.5	142.8
10 years	11.5	142.8

Manager	Title	Age	Since
Peng Zhang PRN	Corporate Officer/Principal	49	2019-11-15
Zhongmin Wang PRN	Corporate Officer/Principal	56	2019-11-15
Baiyong Li CTO	Chief Tech/Sci/R&D Officer	57	2019-11-15

Director	Title	Age	Since
Michelle Xia CHM	Chairman	58	2012-03-18
Baiyong Li BRD	Director/Board Member	57	2019-11-15
Zhongmin Wang BRD	Director/Board Member	56	2019-11-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AKESO, INC.	+0.86%	+24.29%	+249.57%	+515.75%	16.09B
ARGENX SE	+0.24%	+2.39%	+15.57%	+35.09%	35.09B
WUXI APPTEC CO., LTD.	+1.95%	+7.06%	+108.59%	-18.67%	32.89B
BIONTECH SE	-0.92%	-2.54%	+28.74%	-33.21%	27.09B
INSMED INCORPORATED	-1.55%	+4.46%	+34.99%	+333.64%	19.48B
SUMMIT THERAPEUTICS INC.	-5.18%	+4.80%	+198.24%	+2,239.29%	19.46B
WUXI BIOLOGICS (CAYMAN) INC.	+0.88%	+7.13%	+154.00%	-62.61%	14.8B
GENMAB A/S	-0.07%	+3.01%	-23.33%	-44.07%	13.63B
EXELIXIS, INC.	-0.89%	-0.87%	+96.77%	+103.62%	12.13B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.09%	+14.29%	+159.07%	-	11.32B
Average	-0.36%	+6.29%	+102.22%	+340.98%	20.2B
Weighted average by Cap.	-0.28%	+5.32%	+91.03%	+303.24%

	2025 *	2026 *
Net sales	3.52B 3.85B 491M 421M 392M 365M 674M 42.27B 752M 4.74B 1.79B 19.82B 1.84B 1.8B 72.85B	5.44B 5.95B 758M 650M 606M 564M 1.04B 65.27B 1.16B 7.32B 2.76B 30.6B 2.84B 2.78B 112B
Net income	87.64M 95.8M 12.21M 10.47M 9.76M 9.08M 16.75M 1.05B 18.71M 118M 44.5M 493M 45.79M 44.84M 1.81B	880M 962M 123M 105M 98.03M 91.21M 168M 10.56B 188M 1.18B 447M 4.95B 460M 450M 18.2B
Net Debt	221M 242M 30.78M 26.41M 24.61M 22.9M 42.24M 2.65B 47.17M 297M 112M 1.24B 115M 113M 4.57B	-3.13B -3.42B -436M -374M -348M -324M -598M -37.53B -668M -4.21B -1.59B -17.59B -1.63B -1.6B -64.67B